S&P Futures
4,013.25 -19.25 (-0.48%) Dow Futures
33,649.00 -136.00 (-0.40%) Nasdaq Futures
11,888.25 -79.75 (-0.67%) Russell 2000 Futures
1,885.80 -7.70 (-0.41%) Crude Oil
76.89 -1.01 (-1.30%) Gold
1,920.10 -19.10 (-0.98%)
Aldeyra Therapeutics, Inc. (ALDX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.09 |
| Open | 6.04 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 5.76 - 6.09 |
| 52 Week Range | 2.36 - 7.99 |
| Volume | |
| Avg. Volume | 341,788 |
| Market Cap | 337.892M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.11 |
| Earnings Date | Mar 15, 2023 - Mar 20, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.88 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ALDX
Related Research
- Aldeyra Therapeutics, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat15 hours agoMorningstar
- Simply Wall St.
Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit
Insiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to...
- Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
LEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.
- Benzinga
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure. ADX-629 and placebo were well tolerated, and no safety concerns were noted. Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision D
